Effect of sibutramine HCl on cardiac hERG K+ channel

Molecular and Cellular Biochemistry

Volumn 320, Issue 1-2, 2009, Pages 125-131

  Kim, Ki Suk ^a   Kim, Eun Joo ^a   Lee, Hyang Ae ^a   Park, Sang Joon ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Cardiac action potential duration; HERG potassium channel; Long QT syndrome; S6 residue hERG mutant; Sibutramine HCl

Indexed keywords

POTASSIUM CHANNEL HERG; PROTEIN S6; SIBUTRAMINE;

ARTICLE; CELL STRAIN HEK293; CHANNEL GATING; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HEART MUSCLE POTENTIAL; HUMAN; HUMAN CELL; IC 50; MEMBRANE DEPOLARIZATION; MUTATION; POTASSIUM CURRENT; PROTEIN EXPRESSION; QT INTERVAL;

ANIMALS; APPETITE DEPRESSANTS; CELL LINE; CYCLOBUTANES; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; ION CHANNEL GATING; MUTAGENESIS, SITE-DIRECTED; MYOCARDIUM; PATCH-CLAMP TECHNIQUES;

EID: 58049189537     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9914-2     Document Type: Article

References (13)

1. Witchel HJ, Hanconx JC (2000) Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 27:753-766. doi: 10.1046/j.1440-1681.2000.03337.x
2. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH (2000) QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048-1052. doi: 10.1016/S0140-6736(00)02035-3
3. Need AC, Motulsky AG, Goldstein DB (2005) Priorities and standards in pharmacogenetic research. Nat Genet 37:671-681. doi: 10.1038/ng1593
4. Ryan DH, Kaiser P, Bray GA (1995) Sibutramine: A novel new agent for obesity treatment. Obes Res 3:553S-559S
5. Harrison-Woolrych M, Clark DW, Hill GR, Rees MI, Skinner JR (2006) QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 61:464-469. doi: 10.1111/j.1365-2125.2006.02574.x
6. Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 81:299-307. doi: 10.1016/ 0092-8674(95)90340-2
7. Mitcheson JS, Sanguinetti MC (1999) Biophysical properties and molecular basis of cardiac rapid and slow delayed rectifier potassium channels. Cell Physiol Biochem 9:201-216. doi: 10.1159/000016317
8. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 57:367-374
9. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333. doi: 10.1073/pnas.210244497
10. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803. doi: 10.1016/0092-8674(95)90358-5
11. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J (2002) The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300:543-548. doi: 10.1124/ jpet.300.2.543
12. Spector PS, Curran ME, Keating MT (1996) Class III antiarrhymic drugs block HERG, a human cardiac delayed rectifier K + channel. Open-channel block by methanesulfonanilides. Circ Res 78:499-503
13. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC (2004) Physicochemical features of the HERG channel drug binding site. J Biol Chem 279:10120-10127. doi: 10.1074/jbc.M310683200